T1	CHEM 46 57	Rivaroxaban
#1	AnnotatorNotes T1	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T2	DISO 76 98	tromboembolismo venoso
#2	AnnotatorNotes T2	C1861172; Venous Thromboembolism; Disease or Syndrome
T3	PROC 127 212	Ensayo clínico multicéntrico, aleatorizado, abierto, controlado con comparador activo
T4	PROC 219 253	evaluar la eficacia y la seguridad
#3	AnnotatorNotes T4	C0511730; Identify product efficacy and safety issues; Health Care Activity
T5	DISO 338 360	tromboembolismo venoso
#4	AnnotatorNotes T5	C1861172; Venous Thromboembolism; Disease or Syndrome
T6	DISO 390 404	Coágulo venoso
T7	ANAT 398 404	venoso
#5	AnnotatorNotes T7	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T8	DISO 466 482	Trombosis venosa
#6	AnnotatorNotes T8	C0042487; Venous Thrombosis; Pathologic Function
T9	DISO 546 568	tromboembolismo venoso
#7	AnnotatorNotes T9	C1861172; Venous Thromboembolism; Disease or Syndrome
T10	PROC 592 603	tratamiento
#8	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	PROC 768 792	consentimiento informado
#9	AnnotatorNotes T11	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T12	CHEM 652 655	HNF
#10	AnnotatorNotes T12	C0019134; heparin; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T13	CHEM 657 661	HBPM
#11	AnnotatorNotes T13	C0019139; Heparin, Low-Molecular-Weight; Organic Chemical · Pharmacologic Substance
T14	CHEM 664 676	fondaparinux
#12	AnnotatorNotes T14	C1098510; fondaparinux; Organic Chemical · Pharmacologic Substance
T15	PROC 694 720	tratamiento anticoagulante
#13	AnnotatorNotes T15	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T16	DISO 865 875	Hemorragia
#14	AnnotatorNotes T16	C0019080; Hemorrhage; Pathologic Function
T17	DISO 900 910	hemorragia
#15	AnnotatorNotes T17	C0019080; Hemorrhage; Pathologic Function
T18	PROC 993 996	FGe
#16	AnnotatorNotes T18	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T19	PROC 931 957	tratamiento anticoagulante
#17	AnnotatorNotes T19	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T20	PROC 961 991	Filtración glomerular estimada
T21	DISO 1022 1033	Hepatopatía
#18	AnnotatorNotes T21	C0023895; Liver diseases; Disease or Syndrome
T22	DISO 1046 1058	coagulopatía
#19	AnnotatorNotes T22	C0005779; Blood Coagulation Disorders; Disease or Syndrome
T23	DISO 1082 1092	hemorragia
#20	AnnotatorNotes T23	C0019080; Hemorrhage; Pathologic Function
T24	PROC 1256 1274	Cifra de plaquetas
T25	PROC 1177 1194	bilirrubina total
#21	AnnotatorNotes T25	C0201913; Bilirubin, total measurement; Laboratory Procedure
T26	PROC 1216 1235	bilirrubina directa
#22	AnnotatorNotes T26	C0201916; Bilirubin, direct measurement; Laboratory Procedure
T27	ANAT 1265 1274	plaquetas
#23	AnnotatorNotes T27	C0005821; Blood Platelets; Cell
T28	DISO 1291 1312	Hipertensión arterial
#24	AnnotatorNotes T28	C0020538; Hypertensive disease; Disease or Syndrome
T29	CHEM 1411 1466	inhibidores potentes de la isoenzima CYP3A4 y de la GPP
T30	CHEM 1700 1729	inductores potentes de CYP3A4
T31	CHEM 1488 1555	inhibidores de la proteasa del virus de la inmunodeficiencia humana
#25	AnnotatorNotes T31	C0162714; HIV Protease Inhibitors; Pharmacologic Substance
T32	CHEM 1563 1585	antimicóticos azólicos
#26	AnnotatorNotes T32	C0360363; Azole antifungal; Organic Chemical · Pharmacologic Substance
T33	CHEM 1587 1598	ketoconazol
#27	AnnotatorNotes T33	C0022625; ketoconazole; Organic Chemical · Pharmacologic Substance
T34	CHEM 1600 1611	itraconazol
#28	AnnotatorNotes T34	C0064113; itraconazole; Organic Chemical · Pharmacologic Substance
T35	CHEM 1613 1624	voriconazol
#29	AnnotatorNotes T35	C0393080; voriconazole; Organic Chemical · Pharmacologic Substance
T36	CHEM 1627 1638	posaconazol
#30	AnnotatorNotes T36	C0936148; posaconazole; Organic Chemical · Pharmacologic Substance
T37	CHEM 1741 1752	rifampicina
#31	AnnotatorNotes T37	C0035608; rifampin; Antibiotic · Organic Chemical
T38	CHEM 1754 1764	rifabutina
#32	AnnotatorNotes T38	C0140575; rifabutin; Antibiotic · Organic Chemical
T39	CHEM 1766 1778	fenobarbital
#33	AnnotatorNotes T39	C0031412; phenobarbital; Organic Chemical · Pharmacologic Substance
T40	CHEM 1780 1789	fenitoína
#34	AnnotatorNotes T40	C0031507; phenytoin; Organic Chemical · Pharmacologic Substance
T41	CHEM 1792 1805	carbamazepina
#35	AnnotatorNotes T41	C0006949; carbamazepine; Organic Chemical · Pharmacologic Substance
T42	PROC 1857 1880	métodos anticonceptivos
#36	AnnotatorNotes T42	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T43	PROC 2008 2019	tratamiento
#37	AnnotatorNotes T43	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T44	CHEM 2037 2055	fármaco en estudio
#38	AnnotatorNotes T44	C0013230; Investigational New Drugs; Pharmacologic Substance
T45	PROC 2095 2109	procedimientos
#39	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T46	PROC 2234 2248	aleatorización
#40	AnnotatorNotes T46	C0034656; Randomization; Research Activity
T47	ANAT 92 98	venoso
#41	AnnotatorNotes T47	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T48	CHEM 257 268	rivaroxaban
#42	AnnotatorNotes T48	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T49	PROC 274 299	régimen de dosis ajustado
T50	ANAT 354 360	venoso
#43	AnnotatorNotes T50	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T51	ANAT 562 568	venoso
#44	AnnotatorNotes T51	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T52	ANAT 430 439	sanguíneo
#45	AnnotatorNotes T52	C0005767; Blood; Body Substance
T53	ANAT 476 482	venosa
#46	AnnotatorNotes T53	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T54	PROC 620 648	pauta posológica terapéutica
T55	CHEM 706 720	anticoagulante
#47	AnnotatorNotes T55	C0003280; Anticoagulants; Pharmacologic Substance
T56	CHEM 943 957	anticoagulante
#48	AnnotatorNotes T56	C0003280; Anticoagulants; Pharmacologic Substance
T57	PROC 1119 1122	ALT
#49	AnnotatorNotes T57	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T58	CHEM 1177 1188	bilirrubina
#50	AnnotatorNotes T58	C0005437; Bilirubin; Biologically Active Substance · Organic Chemical
T59	CHEM 1216 1227	bilirrubina
#51	AnnotatorNotes T59	C0005437; Bilirubin; Biologically Active Substance · Organic Chemical
T60	ANAT 1304 1312	arterial
#52	AnnotatorNotes T60	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T61	DISO 1917 1934	Hipersensibilidad
#53	AnnotatorNotes T61	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T62	CHEM 2160 2167	fármaco
#54	AnnotatorNotes T62	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T63	Date 13 17	2014
T64	Route 58 62	oral
#55	AnnotatorNotes T64	C1527415; Oral Route of Drug administration; Functional Concept
T65	LIVB 66 71	niños
#56	AnnotatorNotes T65	C0008059; Child; Age Group
T66	LIVB 328 333	niños
#57	AnnotatorNotes T66	C0008059; Child; Age Group
T67	PHYS 424 439	flujo sanguíneo
#58	AnnotatorNotes T67	C0232338; Blood flow; Physiologic Function
T68	LIVB 512 519	Sujetos
#59	AnnotatorNotes T68	C0681850; Study Subject; Group
T69	Age 520 541	de 6 meses a <18 años
T71	Duration 729 749	un mínimo de 90 días
T73	LIVB 829 835	sujeto
#60	AnnotatorNotes T73	C0681850; Study Subject; Group
T74	Spec_cue 885 891	riesgo
T75	PHYS 961 982	Filtración glomerular
#61	AnnotatorNotes T75	C0232809; Glomerular filtration; Organ or Tissue Function
T76	Spec_cue 1072 1081	riesgo de
T77	Duration 1378 1387	< 3 meses
T78	LIVB 1519 1555	virus de la inmunodeficiencia humana
#62	AnnotatorNotes T78	C0019682; HIV; Virus
T80	LIVB 1809 1840	Mujeres potencialmente fértiles
#63	AnnotatorNotes T80	C4324275; Woman of childbearing potential; Population Group
T83	Neg_cue 1845 1847	no
T84	PHYS 1892 1900	embarazo
#64	AnnotatorNotes T84	C0032961; Pregnancy; Organism Function
T85	PHYS 1903 1912	lactancia
#65	AnnotatorNotes T85	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T88	Duration 2209 2220	los 30 días
T70	CHEM 2170 2205	producto sanitario en investigación
#66	AnnotatorNotes T70	C0013230; Investigational New Drugs; Pharmacologic Substance (?)
T72	PROC 319 323	peso
#67	AnnotatorNotes T72	C2985231; Body Weight Measurement; Diagnostic Procedure
T79	ANAT 972 982	glomerular
#68	AnnotatorNotes T79	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
A1	Population_data T65 Age
A2	Population_data T66 Age
A3	Assertion T17 Speculated
A4	Assertion T23 Speculated
A5	Assertion T42 Negated
A7	Assertion T56 Contraindicated
A8	Assertion T19 Contraindicated
A9	Status T61 History_of
A10	Assertion T43 Contraindicated
A11	Assertion T44 Contraindicated
#69	AnnotatorNotes T6	C0042487; Venous Thrombosis; Pathologic Function
#70	AnnotatorNotes T54	C4684645; Dosage Regimen; Therapeutic or Preventive Procedure 
#71	AnnotatorNotes T20	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
#72	AnnotatorNotes T24	C0032181; Platelet Count measurement; Laboratory Procedure
T81	Spec_cue 1817 1831	potencialmente
T82	Quantifier_or_Qualifier 1832 1840	fértiles
A12	Assertion T82 Speculated
R1	Speculation Arg1:T74 Arg2:T17	
R2	Speculation Arg1:T76 Arg2:T23	
T86	Quantifier_or_Qualifier 1093 1115	clínicamente relevante
A13	Assertion T86 Speculated
R3	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T86	
R4	Speculation Arg1:T76 Arg2:T86	
R5	Speculation Arg1:T81 Arg2:T82	
R6	Has_Quantifier_or_Qualifier Arg1:T80 Arg2:T82	
R7	Negation Arg1:T83 Arg2:T42	
T87	Neg_cue 2060 2076	Incapacidad para
T89	Observation 2077 2109	colaborar con los procedimientos
A14	Assertion T89 Negated
#73	AnnotatorNotes T89	C0517036; Cooperates with procedures; Finding
R8	Negation Arg1:T87 Arg2:T89	
R9	Has_Route_or_Mode Arg1:T1 Arg2:T64	
R10	Experiences Arg1:T65 Arg2:T1	
R11	Experiences Arg1:T65 Arg2:T2	
R12	Location_of Arg1:T47 Arg2:T2	
T90	Quantifier_or_Qualifier 99 104	agudo
#74	AnnotatorNotes T90	C0439557; Acute phase; Temporal Concept
R13	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T90	
T91	Quantifier_or_Qualifier 361 366	agudo
#75	AnnotatorNotes T91	C0439557; Acute phase; Temporal Concept
R14	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T91	
R15	Location_of Arg1:T50 Arg2:T5	
R16	Experiences Arg1:T66 Arg2:T72	
R17	Experiences Arg1:T66 Arg2:T48	
R18	Used_for Arg1:T48 Arg2:T49	
R19	Experiences Arg1:T66 Arg2:T5	
R20	Location_of Arg1:T7 Arg2:T6	
R22	Location_of Arg1:T53 Arg2:T8	
R23	Has_Age Arg1:T68 Arg2:T69	
R24	Experiences Arg1:T68 Arg2:T9	
R25	Location_of Arg1:T51 Arg2:T9	
R26	Used_for Arg1:T12 Arg2:T54	
R27	Used_for Arg1:T12 Arg2:T10	
R28	Used_for Arg1:T13 Arg2:T10	
R29	Used_for Arg1:T13 Arg2:T54	
R30	Used_for Arg1:T14 Arg2:T10	
R31	Used_for Arg1:T14 Arg2:T54	
R32	Used_for Arg1:T55 Arg2:T15	
R33	Has_Duration_or_Interval Arg1:T55 Arg2:T71	
R34	Experiences Arg1:T68 Arg2:T10	
R35	Experiences Arg1:T68 Arg2:T15	
R36	Has_Duration_or_Interval Arg1:T12 Arg2:T71	
R37	Has_Duration_or_Interval Arg1:T13 Arg2:T71	
R38	Has_Duration_or_Interval Arg1:T14 Arg2:T71	
T92	Observation 812 824	asentimiento
#76	AnnotatorNotes T92	C1302239; Patient consented to clinical trial; Finding (?)
R41	Used_for Arg1:T56 Arg2:T19	
T93	Quantifier_or_Qualifier 876 882	activa
#77	AnnotatorNotes T93	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R42	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T93	
R43	Location_of Arg1:T79 Arg2:T75	
R44	Location_of Arg1:T79 Arg2:T20	
R47	Location_of Arg1:T79 Arg2:T18	
T94	Result_or_Value 998 1017	< 30 ml/min/1,73 m2
R48	Has_Result_or_Value Arg1:T20 Arg2:T94	
R49	Has_Result_or_Value Arg1:T18 Arg2:T94	
R50	Overlap Arg1:T21 Arg2:T22	
R51	Before Arg1:T21 Arg2:T23	
T95	Result_or_Value 1123 1174	> 5 veces el límite superior de la normalidad (LSN)
R53	Has_Result_or_Value Arg1:T57 Arg2:T95	
T96	Result_or_Value 1195 1211	> 2 veces el LSN
R54	Has_Result_or_Value Arg1:T25 Arg2:T96	
T97	Result_or_Value 1236 1251	>20 % del total
R55	Has_Result_or_Value Arg1:T26 Arg2:T97	
R57	Overlap Arg1:T25 Arg2:T26	
T98	Result_or_Value 1275 1287	< 50 x 109/l
R59	Has_Result_or_Value Arg1:T24 Arg2:T98	
R60	Location_of Arg1:T60 Arg2:T28	
T99	Result_or_Value 1327 1355	> percentil 95 según la edad
R61	Has_Result_or_Value Arg1:T28 Arg2:T99	
T100	CONC 1360 1377	Esperanza de vida
#78	AnnotatorNotes T100	C0023671; Life Expectancy; Group Attribute
R62	Has_Duration_or_Interval Arg1:T100 Arg2:T77	
#79	AnnotatorNotes T29	C3830624; CYP3A4 Inhibitor; Chemical Viewed Structurally (?) | C3898062; P-glycoprotein Inhibitor; Organic Chemical · Pharmacologic Substance
#80	AnnotatorNotes T30	C3850041; Cytochrome P-450 CYP3A4 Inducers; Pharmacologic Substance (?)
T101	Quantifier_or_Qualifier 1684 1696	concomitante
#81	AnnotatorNotes T101	C0521115; Simultaneous; Temporal Concept
R63	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T101	
R64	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T101	
R65	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T101	
R66	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T101	
R67	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T101	
R68	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T101	
R69	Experiences Arg1:T80 Arg2:T42	
T102	Quantifier_or_Qualifier 1881 1890	adecuados
A6	Assertion T102 Negated
#82	AnnotatorNotes T102	C0205411; Adequate; Qualitative Concept
R70	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T102	
R71	Negation Arg1:T83 Arg2:T102	
R72	Causes Arg1:T43 Arg2:T61	
R73	Causes Arg1:T44 Arg2:T61	
T103	Quantifier_or_Qualifier 2020 2030	comparador
#83	AnnotatorNotes T103	C4553390; Comparator; Intellectual Product
R74	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T103	
A15	Assertion T103 Contraindicated
T104	Observation 2125 2152	Participación en un estudio
R76	Overlap Arg1:T104 Arg2:T88	
R77	Before Arg1:T104 Arg2:T46	
R78	Overlap Arg1:T62 Arg2:T88	
R79	Overlap Arg1:T70 Arg2:T88	
R80	Before Arg1:T62 Arg2:T46	
R81	Before Arg1:T70 Arg2:T46	
T105	Quantifier_or_Qualifier 604 611	inicial
#84	AnnotatorNotes T105	C0205265; Initially; Temporal Concept
R84	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T105	
#85	AnnotatorNotes T86	C5209294; Clinical relevance; Intellectual Product
T106	Observation 885 896	riesgo alto
#86	AnnotatorNotes T106	C0332167; High risk of; Finding
R21	Before Arg1:T106 Arg2:T17	
#87	AnnotatorNotes T104	C1278516; Patient participation status; Finding (?)
#88	AnnotatorNotes T49	C1735490; Adjust medications or medication dose, as appropriate; Health Care Activity (?)
A16	Experiencer T65 Patient
A17	Experiencer T66 Patient
A18	Experiencer T68 Patient
A19	Experiencer T73 Patient
A20	Experiencer T80 Patient
